News
Amazon S3 on MSN3d
Blockbuster drug Humira has new competition. Here’s why that mattersHumira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting ...
AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...
A technological revolution is helping Scripps Research scientists see the molecules that undermine human health, from ...
Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...
Rova-T was supposed to be the cancer drug that would bolster AbbVie’s revenues as revenues from the $20bn a year Humira (adalimumab ... perhaps with the usual pictures of shrinking tumours ...
Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...
AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future ...
AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...
Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback